AGIOS PHARMACEUTICALS, INC.
AGIO · Nasdaq · United States
Share price · AGIO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AGIO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 30 Oct 2026-17.9%
Nothing announced by AGIO that day or the session before.
- 19 Oct 2026+11.4%
Nothing announced by AGIO that day or the session before.
- 30 Jul 2026-6.5%
- 21 Jul 2026-6.7%
Nothing announced by AGIO that day or the session before.
- 7 Jul 2026+17.7%
Nothing announced by AGIO that day or the session before.
- 29 Apr 2026+13.1%
- 20 Apr 2026-23.0%
Nothing announced by AGIO that day or the session before.
- 8 Apr 2026-3.8%
Nothing announced by AGIO that day or the session before.
- 31 Mar 2026+14.3%
Nothing announced by AGIO that day or the session before.
- 24 Dec 2025+18.6%
Nothing announced by AGIO that day or the session before.
Share of unusual movement by asset
For each asset, the share of AGIO's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
Mitapivat(Pyrukynd) | Approved | Pyruvate kinaseSmall molecule | Sickle Cell DiseasePyruvate Kinase DeficiencyBeta-Thalassemia Transfusion-Dependent Beta Thalassemia |
| Approved | Pyruvate kinaseSmall molecule | Beta-Thalassemia Transfusion-Dependent Beta Thalassemia |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2029 (3)
March 2029 (1)
What to watch
June 2029 (1)
What to watch
August 2029 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $55M | $73M | $129M+ $501M short-term inv. | $65M-$59M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $45M | $101M | $100M+ $518M short-term inv. | $101M-$57M operating cash flow | report ↗ |
| 2026-Q1 | $21M | $81M | $114M+ $623M short-term inv. | $99M-$119M operating cash flow | report ↗ |
| 2025-Q3 | $13M | $87M | $93M+ $860M short-term inv. | $103M-$88M operating cash flow | report ↗ |
| 2025-Q2 | $12M | $92M | $81M+ $858M short-term inv. | $112M-$77M operating cash flow | report ↗ |
| 2025-Q1 | $8.7M | $73M | $79M+ $814M short-term inv. | $89M-$111M operating cash flow | report ↗ |
| 2024-Q3 | $9.0M | $72M | $254M+ $751M short-term inv. | —-$84M operating cash flow | report ↗ |
| 2024-Q2 | $8.6M | $77M | $85M+ $485M short-term inv. | $96M-$73M operating cash flow | report ↗ |
| 2024-Q1 | $8.2M | $69M | $119M+ $479M short-term inv. | $82M-$100M operating cash flow | report ↗ |
| 2023-Q3 | $7.4M | $82M | $64M+ $583M short-term inv. | $91M-$62M operating cash flow | report ↗ |
| 2023-Q2 | $6.7M | $69M | $85M+ $618M short-term inv. | $84M-$67M operating cash flow | report ↗ |
| 2023-Q1 | $5.6M | $67M | $104M+ $635M short-term inv. | $81M-$95M operating cash flow | report ↗ |
| 2022-Q3 | $3.5M | $65M | $122M+ $605M short-term inv. | $82M-$71M operating cash flow | report ↗ |
| 2022-Q2 | $5.6M | $75M | $89M+ $731M short-term inv. | $92M-$74M operating cash flow | report ↗ |
| 2022-Q1 | $0.8M | $70M | $80M+ $844M short-term inv. | $95M-$98M operating cash flow | report ↗ |
| 2021-Q3 | $0 | $64M | $400M+ $1000M short-term inv. | $89M-$85M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $54M | $340M | $89M+ $765M short-term inv. | $103M-$373M operating cash flow | report ↗ |
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $37M | $301M | $76M+ $817M short-term inv. | —-$390M operating cash flow | report ↗ |
| 2023-FY | $27M | $296M | $88M+ $689M short-term inv. | $88M-$296M operating cash flow | report ↗ |
| 2022-FY | $14M | $280M | $139M+ $644M short-term inv. | $58M-$309M operating cash flow | report ↗ |
| 2021-FY | $0 | $257M | $203M+ $817M short-term inv. | —-$407M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 40 sales ($4.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-26 | Gheuens Sarah · Chief Medical Officer | Option exercise | 7,866 | $25.01 | $197K | Form 4 |
| 2026-10-26 | Gheuens Sarah · Chief Medical Officer | Open-market sale | 7,866 | $37.69 | $296K | Form 4 |
| 2026-10-26 | Gheuens Sarah · Chief Medical Officer | Option exercise (derivative) | 7,866 | — | — | Form 4 |
| 2026-10-22 | Gheuens Sarah · Chief Medical Officer | Option exercise | 500 | $25.01 | $13K | Form 4 |
| 2026-10-22 | Gheuens Sarah · Chief Medical Officer | Open-market sale | 500 | $37.52 | $19K | Form 4 |
| 2026-10-22 | Gheuens Sarah · Chief Medical Officer | Option exercise (derivative) | 500 | — | — | Form 4 |
| 2026-10-21 | Gheuens Sarah · Chief Medical Officer | Option exercise | 1,489 | $25.01 | $37K | Form 4 |
| 2026-10-21 | Gheuens Sarah · Chief Medical Officer | Open-market sale | 1,489 | $37.53 | $56K | Form 4 |